Form 4: Tempest Therapeutics CEO Stephen Brady Acquires 35,000 Shares
SEC Form 4 Filing
Tempest Therapeutics' CEO, Stephen R. Brady, purchased 35,000 shares of common stock at $2.11 per share on July 3, 2024.
Summary
- On July 3, 2024, Stephen R. Brady, the President and CEO of Tempest Therapeutics, Inc., acquired 35,000 shares of common stock.
- The purchase price was $2.11 per share.
- Following the transaction, Brady directly owns 46,376 shares of Tempest Therapeutics common stock, which includes 11,376 shares acquired under the Issuer's stock purchase plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally a good sign, but the document is simply a regulatory filing and doesn't provide enough information for a strong positive sentiment.
Positives
- The CEO's purchase of a significant number of shares could be interpreted as a positive signal about the company's prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company executive believes the company's stock is undervalued. However, it's just one data point and should be considered alongside other factors when evaluating a company.
Key Dates
| Date | Description |
|---|---|
| 07/03/2024 | Date of transaction: Stephen Brady purchased 35,000 shares of common stock. |
| 07/08/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.